Blood group genotyping by high-throughput DNA analysis applied to 356 reagent red blood cell samples

• Published in: Transfusion (Philadelphia, Pa.) Vol. 51; no. 1; pp. 36 - 42
• Main Authors: Kappler-Gratias, Sandrine, Peyrard, Thierry, Beolet, Marylise, Amiranoff, Denise, Menanteau, Cécile, Dubeaux, Isabelle, Rouger, Philippe, Cartron, Jean-Pierre, Pennec, Pierre-Yves Le, Pham, Bach-Nga
• Format: Journal Article
• Language: English
• Published: Malden, USA Blackwell Publishing Inc 01.01.2011; Wiley
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antibodies; Biological and medical sciences; Blood Group Antigens - genetics; Blood Group Antigens - immunology; Blood groups; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Bone marrow, stem cells transplantation. Graft versus host reaction; Data processing; DNA; Duffy system; Erythrocytes; Erythrocytes - immunology; Genotype; Genotyping; Humans; Medical sciences; Sequence Analysis, DNA - methods; Transfusion; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Red blood cell; Genotype; Blood cell; Blood group; Transfusion; Reagents
• ISSN: 0041-1132; 1537-2995; 1537-2995
• DOI: 10.1111/j.1537-2995.2010.02802.x

BACKGROUND: DNA analysis for the prediction of blood group antigen expression has broad implications in transfusion medicine. It may be of particular interest especially to detect variants, when antigen expression is weak or altered. The use of high‐throughput DNA analysis has never been applied to donors whose red blood cells (RBCs) are selected for reagent RBCs. The aim of this study was to analyze the concordance between the serologic phenotype and that predicted from DNA analysis in panel donors, to determine the benefit of the use of DNA analysis in reagent RBC selection strategy. STUDY DESIGN AND METHODS: The “Panel National de Référence du Centre National de Référence sur les Groupes Sanguins” is a reference reagent mainly used for antibody identification. DNA genotyping of 356 panel donors was performed with BeadChips (human erythrocyte antigen v1.2 BeadChips, BioArray Solutions). The comparison between serologic phenotype and that predicted from DNA analysis held on 8876 paired results obtained from 10 blood group systems and 25 antigens. RESULTS: A 99.95% concordance was observed. Discrepancies in four cases (RH, KEL, LU, and DO systems) were analyzed. Genotyping precisions on the Duffy system were of particular interest. No new rare blood group was observed. CONCLUSION: Systematic DNA analysis of panel donors should unquestionably change the management of reagent RBC selection. The notion of “antigens in double dose” should evolve regarding data obtained from DNA analysis, allowing an improved quality of reagent RBCs for antibody screening and identification.